Hetrombopag ( DrugBank: Hetrombopag )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 60 | Aplastic anemia | 5 |
| 63 | Idiopathic thrombocytopenic purpura | 3 |
60. Aplastic anemia
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05333861 (ClinicalTrials.gov) | May 1, 2022 | 11/4/2022 | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | Primary Immune Thrombocytopenia;Aplastic Anemia | Drug: hetrombopag | Wuhan Union Hospital, China | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting | N/A | N/A | All | 1150 | China | |
| 2 | NCT05018936 (ClinicalTrials.gov) | October 1, 2021 | 19/8/2021 | Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia | Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia: a Prospective Single Arm Study | Aplastic Anemia;Drug Effect | Drug: Hetrombopag | Peking Union Medical College Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 40 | Phase 2/Phase 3 | China |
| 3 | NCT05088642 (ClinicalTrials.gov) | September 28, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects | A Phase I Clinical Study Evaluating the Pharmacokinetics and Safety of Hetrombopag Olamine Tablets in Subjects With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 24 | Phase 1 | China |
| 4 | NCT05088174 (ClinicalTrials.gov) | September 3, 2020 | 12/10/2021 | A Trial of Hetrombopag in Healthy Subjects | A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects | Sever Aplastic Anaemia | Drug: Hetrombopag Olamine Tablet;Ciclosporin Soft Capsule | Jiangsu HengRui Medicine Co., Ltd. | NULL | Completed | 18 Years | 65 Years | All | 26 | Phase 1 | China |
| 5 | NCT04961710 (ClinicalTrials.gov) | September 19, 2019 | 12/7/2021 | Extension Study of Hetrombopag in Severe Aplastic Anemia | Extension Study of Hetrombopag Olamine in Patients With Treatment-naive Severe Aplastic Anemia | Treatment-naive Severe Aplastic Anemia | Drug: Hetrombopag Olamine;Drug: Placebo | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 15 Years | 75 Years | All | 180 | Phase 3 | China |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05333861 (ClinicalTrials.gov) | May 1, 2022 | 11/4/2022 | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA | Primary Immune Thrombocytopenia;Aplastic Anemia | Drug: hetrombopag | Wuhan Union Hospital, China | Jiangsu Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting | N/A | N/A | All | 1150 | China | |
| 2 | NCT02614846 (ClinicalTrials.gov) | August 2015 | 19/11/2015 | Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients | A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura | Chronic Idiopathic Thrombocytopenic Purpura | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | Both | 29 | Phase 1 | China |
| 3 | NCT02403440 (ClinicalTrials.gov) | April 2014 | 20/3/2015 | A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients | A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | Both | 24 | Phase 1 | China |